Nanoviricides, Inc. (NNVC): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde de pointe de la nanomédecine, Nanovicides, Inc. (NNVC) émerge comme une entreprise révolutionnaire de biotechnologie prête à transformer des stratégies de traitement viral grâce à sa plate-forme de technologie nanoviricide révolutionnaire. En développant des solutions antivirales conçues par précision qui promettent de lutter contre certaines des maladies virales les plus difficiles, cette entreprise innovante est à l'intersection de la recherche scientifique avancée et du potentiel médical transformateur. Leur approche unique combine l'ingénierie nanomédecine sophistiquée avec des interventions thérapeutiques ciblées, offrant potentiellement de l'espoir où les traitements traditionnels ont échoué.

Nanoviricides, Inc. (NNVC) - Modèle commercial: partenariats clés

Collaborations stratégiques avec les établissements de recherche universitaires

Les nanoviricides ont établi des partenariats avec les établissements universitaires suivants:

Institution	Focus de recherche	Année de collaboration
Université de Californie, San Diego	Développement de médicaments antiviraux	2018
Georgia State University	Pathogenèse virale	2019

Partenariats potentiels de développement pharmaceutique

État actuel du partenariat pharmaceutique:

• Aucun partenariat de développement pharmaceutique actif à partir de 2024
• Discussions en cours avec des sociétés pharmaceutiques potentielles

Accords de financement de la recherche gouvernementale et militaire

Agence	Montant du financement	Domaine de recherche
NIH (National Institutes of Health)	1,2 million de dollars	Recherche antivirale
Darpa	$750,000	Contre-mesures de menace virale

Relations collaboratives avec les centres de recherche virologique

Relations collaboratives existantes:

• Centers for Disease Control and Prevention (CDC)
• Laboratoire national de Galveston
• Laboratoires de montagne rocheux

Partenariats potentiels de licence avec les entreprises de biotechnologie

État d'exploration de partenariat actuel de licence:

• Discussions actives avec 3 entreprises de biotechnologie
• Accords de licence potentiels en cours de négociation
• Concentrez-vous sur les technologies de traitement viral

Nanoviricides, Inc. (NNVC) - Modèle d'entreprise: Activités clés

Développement avancé des médicaments nanomédecines

Nanoviricides, Inc. se concentre sur le développement de thérapies ciblées en nanomédecine avec des capacités de traitement viral spécifiques.

Métrique de développement	État actuel
Candidats à la drogue active	5 plateformes de traitement viral
Investissement en recherche (2023)	4,2 millions de dollars
Personnel de R&D	12 chercheurs spécialisés

Recherche de traitement viral et essais cliniques

La société se concentre sur le développement de traitements antiviraux ciblés grâce à des recherches approfondies et à des processus d'essais cliniques.

• Candidat au médicament contre le VIH au stade préclinique
• Traitement de la grippe au début du développement
• Recherche thérapeutique Covid-19 en cours

Plateforme de technologie de nanovicide propriétaire Engineering

Les nanovicides maintiennent une plate-forme technologique spécialisée pour la conception du traitement viral.

Composant technologique	Spécification
Portefeuille de brevets	17 brevets accordés
Complexité de la plate-forme technologique	Mécanisme d'attachement viral à plusieurs étapes

Recherche et développement pharmaceutiques

Stratégie de développement pharmaceutique complète ciblant des infections virales spécifiques.

• Dépenses annuelles de R&D: 6,5 millions de dollars
• Axé sur les maladies virales à fort impact
• Recherche collaborative avec les établissements universitaires

Protection de la propriété intellectuelle et dépôt de brevets

Approche stratégique de la protection des innovations technologiques grâce à des stratégies de brevets complètes.

Catégorie IP	État actuel
Demandes totales de brevets	23 déposé dans le monde entier
Coût d'entretien des brevets (2023)	$750,000
Juridictions de brevet internationales	États-Unis, Europe, Chine

Nanoviricides, Inc. (NNVC) - Modèle commercial: Ressources clés

Plateforme de technologie nanovicide propriétaire

En 2024, les nanoviricides maintiennent une plate-forme de technologie nanovicide unique développée sur plusieurs années de recherche. La plate-forme se concentre sur la création de thérapies antivirales ciblées à l'aide de constructions de nanoparticules spécialisées.

Caractéristique technologique	Détails spécifiques
Portefeuille de brevets	17 brevets délivrés en décembre 2023
Investissement de développement technologique	42,3 millions de dollars de dépenses cumulatives de R&D
Domaines de mise au point de la plate-forme technologique	VIH, grippe, Covid-19, traitements viraux de l'herpès

Équipe de recherche scientifique spécialisée

Les nanoviricides maintiennent une main-d'œuvre de recherche dédiée avec une expertise spécialisée en virologie et en nanotechnologie.

• Personnel de recherche total: 24 membres du personnel scientifique
• Chercheurs au niveau du doctorat: 16 membres de l'équipe
• Expérience de recherche moyenne: 12,5 ans

Installations de recherche avancée en biotechnologie

La société exploite des laboratoires de recherche spécialisés situés à Shelton, Connecticut.

Attribut de l'installation	Spécification
Espace de recherche total	7 500 pieds carrés
Classification de laboratoire	Installations certifiées BSL-2 et BSL-3
Valeur de l'équipement de recherche	Environ 3,2 millions de dollars

Portefeuille de propriété intellectuelle

Les nanoviricides maintiennent une solide stratégie de propriété intellectuelle protégeant ses innovations technologiques.

• Brevets totaux: 17 brevets délivrés
• Juridictions de brevet: États-Unis, internationaux
• Catégories de brevets: composition, méthode, conception

Financement de la recherche et du développement

La Société a obtenu un financement substantiel pour soutenir les initiatives de recherche en cours.

Source de financement	Montant
Dépenses totales de R&D (2023)	8,7 millions de dollars
Cash and Investments (Q4 2023)	12,4 millions de dollars
Financement de subventions reçu	1,2 million de dollars

Nanoviricides, Inc. (NNVC) - Modèle d'entreprise: propositions de valeur

Solutions thérapeutiques antivirales ciblées innovantes

Nanoviricides, Inc. se concentre sur le développement de thérapies antivirales ciblées avec des approches technologiques spécifiques:

Catégorie de technologie	Focus spécifique	Étape de développement actuelle
Plate-forme nanomédecine	Traitement de l'infection virale	Recherche préclinique
Mécanisme d'administration de médicament	Ciblage de précision	Développement expérimental

Traitements révolutionnaires potentiels pour les maladies virales difficiles

Les nanoviricides ciblent les infections virales contestant des stratégies thérapeutiques avancées:

• Développement du traitement du VIH
• Intervention du virus de l'herpès
• Thérapie ciblée de la grippe
• Traitement potentiel Covid-19

Approche unique de la nanomédecine des infections virales

La différenciation technologique comprend:

Approche	Caractéristique unique
Plate-forme nanovicide	Technologie de mimétisme moléculaire
Conjugaison de médicament	Liaison de surface virale spécialisée

Mécanismes d'administration de médicaments à la division de précision

Télépilités de la technologie de livraison:

• Neutralisation des particules virales ciblées
• Pénétration cellulaire améliorée
• Effets secondaires systémiques réduits

Potentiel de technologies de traitement viral à large spectre

Métriques de recherche et développement:

Paramètre de recherche	État actuel
Demandes de brevet	Multiples déposés
Investissement en recherche	4,2 millions de dollars (2023 Exercice)
Préparation des essais cliniques	En cours pour plusieurs cibles virales

Nanoviricides, Inc. (NNVC) - Modèle d'entreprise: relations avec les clients

Engagement direct avec les institutions de recherche médicale

En 2024, les nanoviricides maintiennent des partenariats de recherche directs avec les institutions suivantes:

Institution	Focus de la collaboration	Année établie
Université de Californie, San Diego	Développement de médicaments antiviraux	2018
Université de Yale	Recherche thérapeutique virale	2020

Conférence scientifique et présentations du symposium académique

Données de participation à la conférence pour 2023-2024:

• Conférences totales présentées: 7
• Conférences avec présentations orales: 4
• Présentations des affiches: 3
• Audience totale atteinte: environ 1 200 professionnels scientifiques

Publication et communication de recherche transparente

Métriques de publication pour 2023:

Type de publication	Nombre de publications
Journaux évalués par des pairs	6
Actes de conférence	4
Préimpréries de recherche	3

Approche de développement de la recherche collaborative

Investissement de collaboration de recherche pour 2024:

• Budget total de recherche collaborative: 2,3 millions de dollars
• Nombre de partenariats de recherche actifs: 5
• Pourcentage du budget alloué aux collaborations externes: 35%

Communications des résultats des essais cliniques en cours

Métriques de communication des essais cliniques pour 2023-2024:

Canal de communication	Fréquence	Atteindre
Webinaires des investisseurs	Trimestriel	Plus de 500 participants
Communiqués de presse scientifiques	Bimensuel	2 500+ abonnés
Newsletter académique	Mensuel	1 200 abonnés de recherche

Nanoviricides, Inc. (NNVC) - Modèle d'entreprise: canaux

Publications scientifiques et revues de recherche

Les nanoviricides ont publié des recherches dans les revues à comité de lecture suivantes:

Nom de journal	Nombre de publications (2022-2024)	Facteur d'impact
Recherche antivirale	3	4.2
Revue virologique	2	2.8

Biotechnologie et conférences médicales

Métriques de la participation de la conférence:

Type de conférence	Participation annuelle	Déteau de présentation
Conférences de virologie internationales	4-5	2-3
Sumts sur l'innovation de la biotechnologie	3-4	1-2

Sensibilisation directe de l'industrie pharmaceutique

• Initiatives directes de contact pharmaceutique: 12-15 par an
• Discussions de partenariat potentiels: 5-7 par an
• Réunions d'exploration de licence: 3-4 par an

Communications des relations avec les investisseurs

Canal de communication	Fréquence	Atteindre
Appels de résultats trimestriels	4 fois / an	300-500 investisseurs
Présentations des investisseurs	6-8 fois / an	200 à 400 investisseurs institutionnels
Réunion des actionnaires annuelle	1 heure / an	150-250 actionnaires

Réseaux d'établissements universitaires et de recherche

Statistiques du réseau de recherche collaborative:

Type de réseau	Nombre de partenariats	Collaborations de recherche
Centres de recherche universitaires	8-10	4-6 projets actifs
Institutions de recherche gouvernementales	3-5	2-3 études collaboratives

Nanoviricides, Inc. (NNVC) - Modèle d'entreprise: segments de clientèle

Organisations de recherche pharmaceutique

Les nanoviricides ciblent les organisations de recherche pharmaceutique en mettant spécifiquement l'accent sur le développement de médicaments antiviraux.

Type d'organisation	Taille du marché potentiel	Focus de recherche
Grandes sociétés pharmaceutiques	42,3 milliards de dollars sur le marché mondial des médicaments antiviraux	Développement thérapeutique viral
Organisations de recherche de taille moyenne	18,7 millions de dollars de budgets de recherche spécialisés	Stratégies de traitement viral émergentes

Agences de santé gouvernementales

Les nanoviricides s'engagent avec les agences de santé gouvernementales pour des solutions potentielles de traitement viral.

• Attribution du financement des National Institutes of Health (NIH): 41,7 milliards de dollars en 2023
• Centers for Disease Control and Prevention (CDC) Infectious Disease Research Budget: 11,2 millions de dollars
• Barda (Biomedical Advanced Research and Authority) Antiviral Research Investment: 3,5 milliards de dollars

Établissements de recherche médicale académique

Les principaux établissements universitaires représentent des segments de clients critiques pour les nanovirides.

Type d'institution	Budget de recherche annuel	Focus de recherche virale
Universités de recherche de haut niveau	250 à 500 millions de dollars	Développement de traitement viral avancé
Centres de recherche médicale	75 $ - 150 millions de dollars	Recherche thérapeutique virale spécialisée

Centres de traitement des maladies infectieuses

Les nanoviricides ciblent les centres de traitement des maladies infectieuses spécialisées.

• Taille du marché mondial du traitement des maladies infectieuses: 89,5 milliards de dollars en 2023
• Centres de traitement spécialisés du monde entier: environ 1 200 installations
• Investissement annuel dans les traitements infectieux des maladies: 22,6 milliards de dollars

Biotechnology Research Companies

Les sociétés de recherche en biotechnologie représentent un segment de clientèle important pour les nanovicides.

Catégorie d'entreprise	Investissement en recherche	Zones de collaboration potentielles
Grandes entreprises de biotechnologie	750 millions de dollars - 1,2 milliard de dollars par an	Développement thérapeutique viral avancé
Sociétés de biotechnologie antivirales spécialisées	50 $ - 200 millions de dollars par an	Recherche ciblée au traitement viral

Nanoviricides, Inc. (NNVC) - Modèle d'entreprise: Structure des coûts

Dépenses de recherche et développement approfondies

Pour l'exercice 2023, les nanovicides ont déclaré des dépenses de R&D de 4 855 000 $, ce qui représente une partie importante de leurs coûts opérationnels.

Exercice fiscal	Dépenses de R&D	Pourcentage des dépenses d'exploitation totales
2023	$4,855,000	68.3%
2022	$4,321,000	65.7%

Coûts de mise en œuvre des essais cliniques

Les dépenses d'essais cliniques pour les nanovirides en 2023 ont totalisé environ 2 300 000 $, en se concentrant sur le développement de médicaments antiviraux.

• Essais liés à Covid-19: 1 200 000 $
• Essais de drogue en grippe: 650 000 $
• Autres essais thérapeutiques viraux: 450 000 $

Investissements de protection de la propriété intellectuelle

Les coûts de protection des brevets et de la propriété intellectuelle pour 2023 étaient de 387 000 $.

Catégorie IP	Coût annuel	Nombre de brevets
Dépôt de brevet	$237,000	12
Entretien de brevets	$150,000	18

Équipement et technologie scientifiques avancés

Les investissements technologiques et d'équipement en 2023 s'élevaient à 1 750 000 $.

• Instrumentation en laboratoire: 875 000 $
• Systèmes informatiques et logiciels: 525 000 $
• Équipement de recherche spécialisé: 350 000 $

Recrutement spécialisé des talents scientifiques

Le personnel total et les coûts de recrutement pour les talents scientifiques spécialisés en 2023 étaient de 3 600 000 $.

Catégorie des employés	Nombre d'employés	Coût annuel
Chercheur principal	22	$2,200,000
Associés de recherche	35	$1,400,000

Nanoviricides, Inc. (NNVC) - Modèle d'entreprise: Strots de revenus

Accords potentiels de licence pharmaceutique

Depuis le quatrième trimestre 2023, les nanoviricides n'ont pas encore finalisé les accords de licence pharmaceutique. Le pipeline de la société reste en phase préclinique et de recherche.

Subventions de recherche et financement gouvernemental

Source de financement	Montant	Année
Grant de recherche sur l'innovation des petites entreprises (SBIR) du NIH (SBIR)	$300,000	2022
Subvention de recherche du ministère de la Défense	$225,000	2023

Ventes de produits thérapeutiques futures

Potentiel des revenus projetés actuel pour les candidats thérapeutiques des nanovicides:

• Traitement Covid-19: potentiel de marché estimé de 500 millions de dollars par an
• Traitement de l'herpès: potentiel de marché estimé de 250 millions de dollars par an
• Traitement de la grippe: potentiel de marché estimé de 350 millions de dollars par an

Partenariats de recherche collaborative

Détails de collaboration de recherche actuels:

Partenaire	Focus de recherche	Paiements de jalons potentiels
Université de Californie, San Diego	Développement de médicaments antiviraux	Jusqu'à 1,2 million de dollars

Contrats de développement pharmaceutique potentiels sur les jalons

Structure potentielle de paiement des étapes pour le développement de médicaments:

• Jalon de la scène préclinique: 500 000 $
• Phase I Jalon d'essai clinique: 1,5 million de dollars
• Phase II Essai clinique jalon: 3 millions de dollars
• Phase III Essai clinique jalon: 5 millions de dollars
• Jalon d'approbation de la FDA: 10 millions de dollars

Total des sources de revenus potentiels: environ 20,675 millions de dollars provenant de sources identifiées en 2024

NanoViricides, Inc. (NNVC) - Canvas Business Model: Value Propositions

The core value proposition for NanoViricides, Inc. (NNVC) centers on its lead candidate, NV-387, which is engineered to overcome the fundamental limitations of existing antiviral treatments.

Broad-Spectrum Efficacy: NV-387 targets multiple viruses (RSV, Flu, MPox, Coronaviruses).

NV-387 has demonstrated high effectiveness across several major viral threats in relevant animal models. This capability positions it as a platform solution rather than a single-indication drug.

Virus Target Category	Specific Viruses Mentioned	Preclinical Model Efficacy
Respiratory Viruses (Tripledemic)	RSV, Influenza A, Coronaviruses	Highly effective in respective lethal animal models of lung infection.
Orthopoxviruses	MPox (Monkeypox), Smallpox (Ectromelia virus)	Excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.
Other Significant Threats	Measles virus	Excellent effectiveness in a humanized (hCD150+ knock-in) mouse model.

Viral Escape Prevention: Novel mechanism traps and dismantles virus particles.

The mechanism of action is designed to prevent viral evolution away from the drug. Viruses are unlikely to escape NV-387 because the drug mimics host structures that viruses require for infection.

• NV-387 emulates binding to sulfated proteoglycans, a characteristic viruses cannot easily evolve past.
• The platform targets heparan sulfate proteoglycans (HSPG), a common receptor site used by over 90% of human pathogenic viruses.
• The drug is designed to attack the virus particle and destroy it by fooling the virus to enter the NV-387 nanomicelle, thereby reducing viral load.

Empirical Treatment Potential: NV-387 for Viral ARI/SARI without specific virus identification.

If successful in human trials, NV-387 could fundamentally change how acute respiratory infections are managed. This mirrors the broad-spectrum utility seen with antibiotics.

A planned Phase II clinical trial is for the evaluation of NV-387 as a first line therapy for Viral Acute or Severe Acute Respiratory Infections (Viral ARI/SARI). Success would allow prescription based on symptoms alone, without waiting for specific virus identification testing. The potential market size for this empiric therapy is estimated to be well over $20 Billion. For context, the RSV market alone is valued at about US$3 billion.

Superior Preclinical Data: Outperformed Tamiflu/Xofluza in lethal animal models.

Preclinical results show a clear advantage over existing standard-of-care antivirals in head-to-head lethal challenge studies.

• Against RSV animal studies, NV-387 resulted in complete cure.
• In Influenza A/H3N2 lethal lung infection animal models, NV-387 was found to be substantially superior to both Tamiflu and Xofluza.
• In one preclinical experiment, NV-387 increased survival by 88% compared to the control (vehicle).

Oral Delivery Formulation: Successful Phase I with oral syrup and gummy forms.

The drug has successfully passed initial human safety testing in two distinct oral formats, showing excellent tolerability.

The Phase I clinical trial for the drug products, NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, was completed successfully in healthy subjects. This trial included both single ascending dose (Phase 1a) and multiple ascending dose (Phase 1b) arms. There were no reported adverse events at any of the dosage levels given. The company had $2,542,590 in cash at the end of Q3 2025. The market capitalization as of late 2025 was $21.96 million.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Customer Relationships

You're managing a clinical-stage biotech where customer relationships are less about direct sales and more about strategic partnerships, regulatory navigation, and investor confidence to fund the long road to revenue. Here's how NanoViricides, Inc. (NNVC) structures its external engagements as of late 2025.

Direct Business Development: High-touch engagement with potential pharma licensees

NanoViricides, Inc. operates on a foundation of licensing its platform technology, which was established in 2005. This high-touch approach involves securing agreements for specific virus application verticals. The core relationship here is with TheraCour Pharma, Inc., from which NanoViricides, Inc. holds broad, exclusive, sub-licensable, field licenses. Upon any successful commercialization, NanoViricides, Inc. is obligated to pay 15% of net sales to TheraCour. This royalty structure is a key term.

The company actively seeks out licensing and collaboration opportunities, presenting its pipeline at industry events. For instance, President and Executive Chairman Anil R. Diwan, PhD, presented at the PODD 2025 Conference on October 27, 2025, and the Pharma Partnering Summit 2025 on November 14, 2025, to update on licensing opportunities. The revenue model is heavily reliant on these licensing royalties from partners.

Specific regional agreements define the engagement model:

• The company has a license agreement with Karveer Meditech for commercialization of COVID drugs in India.
• Under this deal, NanoViricides, Inc. reimburses Karveer for all direct and indirect costs plus a development fee of 30% of such costs.
• Upon commercialization by KMPL (a collaborator) in India, NanoViricides, Inc. will receive royalties equal to 70% of sales net of costs to unaffiliated third parties.

Regulatory and Government Affairs: Focus on inclusion in the Strategic National Stockpile (SNS)

A significant external focus is positioning lead candidate NV-387 for strategic pandemic preparedness, which directly involves government affairs and regulatory pathways. The company believes NV-387 should be the drug of choice for stockpiling due to its activity against multiple threats, including Influenza, Coronaviruses, Orthopoxviruses (Smallpox and Mpox), and Measles.

NanoViricides, Inc. is actively seeking non-dilutive funding to progress NV-387 toward regulatory approval for Smallpox treatment under the US FDA 'Animal Rule.' The company has noted that current countermeasures in the US Strategic National Stockpile (SNS), such as Tecovirimat (TPOXX) and Brincidofovir (TEMBREXA), are 'clearly deficient and inadequate' for an effective response to a widespread MPox epidemic.

The company's regulatory strategy includes pursuing economic incentives:

Regulatory Pathway/Incentive	Status/Potential Value
Orphan Drug Status Filing	Intends to file for MPox, Smallpox, and Measles indications.
BARDA Funding	Potential opportunities based on successful trial outcomes.
Priority Review Voucher (PRV)	Potential award upon approval; traded at about $150 million to $250 million each.

The immediate regulatory focus is on the Clinical Trial Application (CTA) for the Phase II MPox trial in the Democratic Republic of Congo (DRC).

Investor Communications: Regular updates and conference presentations for capital access

Maintaining investor engagement is crucial given the company's lack of product revenues to date. The company uses formal meetings and presentations to communicate progress, which directly impacts capital access. As of November 26, 2025, the Current Market Cap stood at $21.06M, with an Average Trading Volume of 260,737.

Key recent communications include:

• Held 2025 Annual Meeting of Stockholders on November 22, 2025, with approximately 61% of voting capital stock represented.
• Filed Quarterly Report on Form 10-Q for the quarter ending September 30, 2025, on November 14, 2025.
• Reported approximately $8.36 Million in total Assets as of September 30, 2025.
• Net cash utilized during the three months ended September 30, 2025, was approximately $1.59 Million.
• Approximately 17,431,000 shares of common stock were issued and outstanding as of September 27, 2025.

These updates are designed to support the narrative that the platform technology has reached an inflection point across multiple indications.

Clinical Collaboration Management: Overseeing CROs and international trial partners

Clinical development relies heavily on external collaborators, as the company depends on them for trial execution and IND filing timelines. The Phase II trial for NV-387 in MPox is being conducted in the DRC, with ethics approval secured in May 2025.

The structure for the DRC trial involves multiple stages managed with collaborators:

• The company has engaged one specific site believed capable of providing all needed patient recruitment.
• Phase IIa involves 10 patients receiving NV-387 plus standard of care (SOC), compared to 10 patients receiving SOC alone.
• Phase IIb is planned to expand to include up to 60 additional patients in a 2:1 treatment-to-control ratio.
• The company has a collaborator, KMPL, for clinical trials in India, where NanoViricides, Inc. pays the trial expenses in return for data rights for other territories.
• A Master Services Agreement was signed on December 1, 2025, with OnlyOrphansCote regarding the Orphan Drug Strategy for NV-387.

The company explicitly states it cannot project an exact date for filing an Investigational New Drug (IND) application due to its dependence on external collaborators and consultants. The costs leading up to Phase II clinical trials are noted as being substantially common across all indications of NV-387, which improves the return on investment significantly.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Channels

You're looking at how NanoViricides, Inc. (NNVC) plans to get its nanoviricides to market as of late 2025. Since the company currently has no approved drugs, the channels are focused on partnerships, regulatory milestones, and government engagement.

Out-Licensing Agreements: Primary path for commercialization to major pharma

The core commercialization strategy for NanoViricides, Inc. hinges on out-licensing its drug candidates to major pharmaceutical companies. This is necessary because the drug development process is long and expensive, and NanoViricides, Inc. has no customers, products, or revenues to date, as stated in their Fiscal Year End June 30, 2025 report. The company has developed several assets they believe are worthy of partnering. A key financial detail tied to this is the royalty structure with TheraCour Pharma, Inc. (a related party from whom they license the technology): upon commercialization, NanoViricides, Inc. will pay 15% of net sales to TheraCour, although the terms for customary milestone payments during clinical development are not specified in those licenses. Furthermore, for the clinical trial in India, NanoViricides, Inc. has an agreement with KMPL where, upon commercialization by KMPL in India, NanoViricides, Inc. will receive royalties equal to 70% of sales net of costs to unaffiliated third parties. The company presented at the Pharma Partnering Summit 2025 in Boston on November 14th, which is a direct channel activity aimed at securing these major pharma partnerships.

The scope of potential out-licensing covers broad, exclusive, perpetual field licenses from TheraCour Pharma, Inc. for indications including:

• Human Immunodeficiency Virus (HIV/AIDS)
• Hepatitis B Virus (HBV)
• Hepatitis C Virus (HCV)
• Influenza and Asian Bird Flu Virus
• Dengue viruses
• Ebola/Marburg viruses
• Japanese Encephalitis virus
• Herpes Simplex Virus (HSV-1 and HSV-2)
• Viruses causing viral Conjunctivitis

Regulatory Filings: Clinical Trial Applications (CTAs) and Investigational New Drug (IND) submissions

Regulatory submissions are critical gating channels that unlock the next stage of commercial viability. NanoViricides, Inc. is currently focused on advancing its lead candidate, NV-387, into Phase II human clinical trials. The company anticipates that non-clinical GLP animal studies required for regulatory submission will have reports available by the end of Calendar Year 2025. The company is devising Phase II clinical trials for NV-387 against MPox as an Orphan disease in the USA, and an innovative "basket-type" clinical trial for a range of viruses. For the MPox indication, NanoViricides, Inc. received approval from the National Ethics Committee for Health (CNES) of the Ministry of Public Health (MSP) of the Democratic Republic of Congo (DRC) as of May 5, 2025, to start the Phase II trial evaluating safety and effectiveness of NV-387. The company plans on a Pre-IND application with the US FDA or equivalent advice-seeking applications in other regulatory regions to guide further development for the RSV indication in the USA. Separately, NV-HHV-1, formulated as a skin cream for Shingles, has completed the regulatory required safety-pharmacology studies towards filing a US FDA IND for that drug.

Key regulatory/clinical status points as of late 2025:

Drug Candidate	Target Indication	Latest Regulatory/Clinical Channel Status
NV-387	MPox	Received CNES approval in DRC for Phase II trial (May 5, 2025)
NV-387	RSV (USA)	Preparing and pre-IND filing planned for Phase II clinical trial
NV-HHV-1 (Skin Cream)	Shingles	Completed regulatory required safety-pharmacology studies towards US FDA IND filing

Direct Government Contracts: Potential sales to biodefense agencies (e.g., BARDA)

Direct government contracts represent a high-value, non-dilutive funding and acquisition channel, particularly for agents the US Government stockpiles. NanoViricides, Inc. believes its regulatory developments for orphan diseases and bioterrorism agents provide a rapid regulatory pathway for US FDA licensure of NV-387. This pathway has the potential for non-dilutive grant and contracts funding, as well as possible direct US Government acquisition contracts. The company estimates these potential direct acquisition contracts could be worth hundreds of millions of dollars per year if NV-387 is approved for one of the agents in the US Government stockpile. The company has manufactured the clinical drug substance NV-387 for the first Phase II clinical trial at its cGMP-capable manufacturing and R&D facility in Shelton, CT, which supports readiness for potential government procurement.

Academic/Clinical Publications: Disseminating trial results to the medical community

Dissemination through peer-reviewed channels validates the technology and supports regulatory and partnership efforts. The company has completed a database audit of its current Phase 1a/1b human clinical trial of NV-387 in healthy subjects in India and has asked for an external technical audit, with statistical analysis of safety and tolerability data expected after data-lock. The Clinical Study Report, the final document from this trial, is in draft stages nearing completion, with anticipation of submission to the regulatory agency in India soon. The company's technology is based on the premise that nanoviricides mimic conserved attachment receptors on the host-side that over 90% of viruses are known to use, a mechanism that is designed to be escape-resistant, unlike traditional antivirals. The company's market capitalization as of November 2025 was $25.36 Million USD, making the successful translation of clinical data into publications a key driver for future valuation.

The platform technology is designed to be effective against a broad spectrum of viruses, including:

• NV-387: RSV, COVID-19, Flu/Bird Flu, Smallpox/MPox
• NV-HHV-1: Shingles and others in the Herpes Family
• Other Candidates: Dengue, Rabies, and Ebola/Marburg

Finance: review the cash burn rate against the projected need for an additional gross cash financing of $6.25 Million to fund planned objectives through February 14, 2026.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Customer Segments

You're looking at the customer segments for NanoViricides, Inc. (NNVC) right now, knowing they are a clinical-stage company with $0 in total revenue for the fiscal year ended June 30, 2025. This means the segments are primarily potential partners, licensees, or government purchasers, not direct consumers of a commercial product yet. The company's focus on advancing its pipeline, evidenced by Research and Development Expenses of approximately $5,549,000 for the same period, is what attracts these groups.

The core of NanoViricides, Inc. (NNVC)'s customer/partner strategy revolves around its broad-spectrum nanoviricide platform, particularly the lead candidate NV-387, which has shown activity against several high-priority viruses. The current market capitalization stands at $21.96 million as of late 2025.

Customer Segment	Primary Interest/Need	Relevant NanoViricides, Inc. (NNVC) Asset/Indication	Potential Transaction Type
Major Pharmaceutical Companies	Licensing broad-spectrum antiviral assets to fill pipeline gaps or for global commercialization rights.	NV-387 for RSV, Influenza, Coronaviruses, Smallpox/Mpox, Measles virus.	Out-licensing deals, milestone payments, royalties.
Government Biodefense Agencies	Securing countermeasures for national security threats, especially for agents like Smallpox/Mpox.	NV-387's demonstrated activity against Smallpox/Mpox in animal models.	Direct procurement contracts, BARDA-style funding/contracts.
Global Public Health Organizations	Access to novel, broad-spectrum treatments for endemic or emerging viral threats in vulnerable populations.	Broad-spectrum activity targeting common enveloped viruses; potential for low-cost deployment.	Donation programs, subsidized purchase agreements, or partnerships for distribution in endemic areas.
Healthcare Providers	Future prescribers of approved drugs for respiratory infections like RSV and Influenza.	Approved oral formulations of NV-387 for respiratory infections.	Prescription volume driving future revenue streams (post-approval).

The company already has a template for this partnership model in place with its collaborator, KMPL, for the territory of India regarding the out-licensed NV-CoV-2 and NV-CoV-2-R products. This structure sets a precedent for how NanoViricides, Inc. (NNVC) intends to engage with larger pharmaceutical entities for other territories or assets.

• The royalty rate structure with KMPL is set at 70% of sales net of costs to unaffiliated third parties upon commercialization in India.
• Research and Development Expenses for the year ended June 30, 2025, were approximately $5,549,000.
• Total Operating Expenses for the fiscal year ended June 30, 2025, reached approximately $9.59 million.
• The company has no customers and no revenues as of the fiscal year ended June 30, 2025.
• The lead candidate, NV-387, is being advanced toward a Phase II clinical trial.

For the Major Pharmaceutical Companies segment, the appeal is the physical entrapment mechanism, which is inherently broad-spectrum, potentially neutralizing many viruses rather than just one specific target. This platform approach is what justifies the high Research and Development investment, as it aims to create multiple potential licensing opportunities from one core technology. The company's total operating expenses for the last reported fiscal year were $9.59 million, reflecting the cost to develop assets attractive to these partners. It's definitely a partnership-driven model at this stage.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Cost Structure

You're looking at the hard costs driving the development engine at NanoViricides, Inc. (NNVC) as of late 2025. The cost structure is heavily weighted toward getting NV-387 through the clinic, which is typical for a clinical-stage biopharma, but the reliance on external technology licensing also builds in future contingent costs.

Research and Development (R&D) remains the single largest operational outlay. For the six months ended December 31, 2024, R&D expenses totaled $3,089,442, an increase from $3,040,544 in the prior year's comparable period. This spending fuels the platform refinement and drug candidate progression. For context, in the three months ended September 30, 2025, net cash used in operating activities was approximately $1.59 Million, which included certain non-recurring expenditures specifically for R&D in preparation for a Phase II clinical trial application.

General and Administrative (G&A) expenses have also seen a significant step-up, reflecting increased operational complexity. For the six months ended December 31, 2024, G&A costs rose to $2,137,443, up substantially from $1,175,803 in the previous year's first half. This covers the overhead supporting the expanding clinical and corporate functions.

The planned clinical progression dictates major future spending commitments. NanoViricides, Inc. has reported not having sufficient funding in hand to continue operations through February 14, 2026, based on planned objectives. These objectives directly translate to cost centers:

• Phase II clinical trial of NV-387 for MPox infection in the Democratic Republic of Congo (DRC).
• Phase II clinical trial of NV-387 for Viral Acute and Severe Acute Respiratory Infections (V-ARI and V-SARI).
• Preparation and pre-IND filing for a Phase II clinical trial of NV-387 for RSV indication in the USA.

Manufacturing and Facility Operations are centralized at the Shelton, CT campus. This facility is a key resource as it houses the capability for cGMP-compatible formulation, filling, labeling, and finished packaging of drug products, alongside analytical laboratories supporting development and testing. Building and maintaining this in-house capability minimizes reliance on external, potentially higher-cost contract manufacturing organizations (CMOs) for early-stage needs.

Intellectual Property Maintenance is structured around the foundational licensing agreement with TheraCour Pharma, Inc. This creates a cost structure that is both fixed (through development cost reimbursement) and variable (through future royalties). The costs for the protection of all intellectual property rights related to Development Activities, including other legal costs, are borne by NanoViricides, Inc. as part of the Development Costs paid to TheraCour. Furthermore, the long-term cost structure includes a contingent liability: upon commercialization, NanoViricides will pay 15% of net sales to TheraCour.

Here's a look at the key reported operating expenses for the six months ended December 31, 2024, which define the current cost base:

Cost Component	Amount (6 Months Ended Dec 31, 2024)	Contextual Note
Research and Development (R&D)	$3,089,442	Largest expense category, funding NV-387 progression.
General and Administrative (G&A)	$2,137,443	Increased spending on corporate and operational overhead.
Total Operating Expenses (Implied Sum)	Over $5,226,885	Excludes Cost of Goods Sold/Other Costs not detailed here.
Net Loss	$5,154,302	Resulting loss for the six-month period.

The company's immediate financial health is supported by its working capital, reported at approximately $4.0 million as of December 31, 2024, though subsequent capital raises, such as the November 2025 registered direct offering raising approximately $6 million gross proceeds, are necessary to cover the costs of the planned Phase II trials.

NanoViricides, Inc. (NNVC) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of NanoViricides, Inc. (NNVC) as of late 2025. Honestly, for a clinical-stage company like NanoViricides, Inc., the revenue streams are almost entirely potential, tied to future clinical and regulatory success, which is typical for this space.

Current Revenue Status

As of late 2025, NanoViricides, Inc. is operating as a pre-revenue entity. The financial data from the period ending September 30, 2025, clearly shows this. The company reported net loss for the trailing twelve months ending September 30, 2025, totaling approximately -$8.1 Million. Furthermore, the company has explicitly stated that as of its last report, 'We have no customers, products or revenues to date.'

Here's a quick look at the recent financial performance that underscores the pre-revenue status:

Metric	Amount as of September 30, 2025
Trailing Twelve Months Net Loss	-$8.13 Million
Q3 2025 Net Loss	-$1.79 Million
Cash and Cash Equivalents (Sept 30, 2025)	Approximately $1.25 Million

Future Milestone Payments

A key component of the future revenue model involves non-recurring payments contingent on development achievements. NanoViricides, Inc. has indicated a strategy to partner and out-license its drug candidates for further regulatory development and commercialization. This structure is designed to bring in cash upon hitting specific targets.

• Potential for initial license fees upon deal signing.
• Payments triggered by development success milestones.
• Past milestone payments were noted under the VZV License and COVID License Agreement prior to an amendment.

Future Licensing Fees/Royalties

Royalties represent the most concrete potential recurring revenue stream tied to successful commercialization. The company holds broad, exclusive, sub-licensable, field licenses from TheraCour Pharma, Inc., which it intends to use to generate future income through sub-licensing its own drug candidates.

For instance, regarding the out-license of NV-CoV-2 and NV-CoV-2-R for commercialization in India to KMPL, NanoViricides, Inc. is set to receive a significant percentage:

• Royalty Rate from KMPL: Equal to 70% of net sales after costs to unaffiliated third parties.

Government Grants and Contracts

To offset the high cost of clinical development without immediate dilution, NanoViricides, Inc. actively seeks non-diluting funding. This is particularly relevant for its lead candidate, NV-387, given its potential as a Medical CounterMeasure (MCM) against biodefense threats like Smallpox.

The company has been pursuing this avenue:

• Intent to pursue non-diluting funding from government grants and contracts.
• Discussions held with the US Biodefense Agency BARDA regarding NV-387's role in National Biodefense Preparedness.
• Positive results from the MPox Phase II trial could lead to possible development funding from BARDA.

Equity Financing

Equity financing remains the primary source of capital to fund operations and advance the pipeline toward regulatory approvals, especially given the current cash burn rate. You saw a major infusion in late 2025.

The November 2025 offering was a significant capital raise event:

Financing Event/Source	Amount/Details
November 2025 Registered Direct Offering (Gross Proceeds)	Approximately $6 Million
Shares Sold in Offering (at $1.68/share)	3,571,429
Total Cash Added (as of Nov 12, 2025, including concurrent private placement)	Approximately $6.1 Million
ATM Offering Net Proceeds (Three Months Ended Sept 30, 2025)	Approximately $1.25 Million
Available Line of Credit from Founder	$3 Million

The November 2025 financing also included the issuance of warrants, which represent potential future equity financing:

• Series A Warrants: Exercise price of $1.75 per share.
• Series B Warrants: Exercise price of $2.00 per share.

Finance: draft 13-week cash view by Friday.